Company news
Argent Biopharma Ltd news in 2023
Argent Biopharma Ltd's news releases, calls and decks from 2023, newest first.
Company Update & Capital Raising
December 21, 2023
Retraction of Statement
December 20, 2023
Pause in trading
December 20, 2023
Share Purchase Plan Closed
August 29, 2023
Pre-clinical Trial Results on CimetrA
August 14, 2023
MGC Pharma Launches Share Purchase Plan
August 1, 2023
MGC receives permission for first import of Psilocybin
July 30, 2023
Commitments Received for GBP 0.7m
July 14, 2023
AMC Places Second Order of ArtemiC for US$1M
July 6, 2023
Malta Production Facility Receives EU-GMP Approval
May 1, 2023
Fundraise closed raising up to a total of GBP 2.09m
April 13, 2023
CannEpil now available by Named Patient Request in UK
April 11, 2023
Funding Commitments Received for GBP 1.8m
April 11, 2023
MGC Receive Permission for Psilocybin Research & Development
April 2, 2023
ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
March 20, 2023
Completion of CimetrA Mechanism of Action study
March 6, 2023
Provision of US$600,000 Funding and change of CFO
February 3, 2023
Refinancing and Extension to Convertible Security Agreements
February 2, 2023
Results of CimetrA bioanalytics pre-clinal trial
January 9, 2023
Internal Costs Review Completed and Board Change
January 2, 2023